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1. Introduction  
Recent work exploring the effects of abusing alcohol, central stimulants, and opiates on the 
central nervous system (CNS) have demonstrated a variety of adverse effects related to 
mental health. In several laboratories and clinics substantial damages of brain function are 
seen to result from these drugs. Among the harmful effects of the abusing drugs on brain 
are those contributing to accelerated obsolescence. These putative aging effects including 
inhibition of neurogenesis and enhanced apoptosis underline the dark side of drug 
addiction and will doubtlessy be a challenge for future research (Carvalho, 2009). An 
observation that has received special attention during recent years is that chronic drug users 
display pronounced impairment in brain areas associated with executive and memory 
function (Ersche et al., 2006).  
Addiction to drugs is characterized as a compulsive behavior, including drug seeking, drug 
use, and drug cravings but it is also considered as a disorder of altered cognition (Gould, 
2010). Indeed, brain areas and processes involved in drug addiction substantially overlap 
with those known to be of relevance for cognitive functions. Studies have indicated that 
abusing drugs may alter the normal structure in these regions and influence functions that 
induce cognitive shifts and promote continued drug use. Processes during early stages of 
drug abuse is suggested to promote strong maladaptive connections between use of drugs 
and environmental input underlying future cravings and drug-seeking behaviors. 
Continued drug use causes cognitive deficits that aggravate the difficulty of establishing 
sustained abstinence (Gould, 2010). In fact, drug addiction has been characterized as a 
disease of "pathological learning" by several investigators (Hyman, 2005; Gould, 2010).  
In earlier days abusing drugs were considered only to induce non-specific effects on the 
brain. Today, it is widely believed that they may produce selective adaptations in very 
specific brain regions. These neuroadaptations have been extensively examined in order to 
clarify mechanisms underlying the development and maintenance of addiction to find 
strategies for relevant treatment. The hippocampus is an area included in the limbic 
structures that is of particular interest, as it is found to be essential for several aspects 
related to the addictive process. A remarked neuroadaptation caused by addictive drugs, 
such as alcohol, central stimulants and opiates involves diminished neurogenesis in the 
subgranular zone (SGZ) of the hippocampus. Indeed, it has been proposed that decreased 
adult neurogenesis in the SGZ could modify the hippocampal function in such a way that it 
contributes to relapse and a maintained addictive behavior  (Arguello et al., 2008). It also 
www.intechopen.com
 
Brain Damage – Bridging Between Basic Research and Clinics 222 
raises the possibility that decreased neurogenesis may contribute to cognitive deficits 
elicited by these abusing drugs. 
In addition to hippocampal structures the prefrontal cortex and its different subregions have 
also been hypothesized to represent this cognitive control system (George et al., 2010; 
Ridderinkhof et al., 2004). Neurons in the dorsolateral prefrontal cortex are suggested to be 
involved in activity that in delayed matching to sample tasks persists throughout the delay 
period (Weiss and Disterhoft, 2011). Moreover, age-related changes in the prefrontal cortex 
microcolumnar organization are shown to correlate with age-related declines in cognition. 
Activity that persists beyond the induction of a specific stimulus is believed to mediate 
working memory processes, and disruption of those processes is related to memory deficits 
that often accompany the aging process. The prefrontal cortex is known as an area with 
enhanced vulnerability to alcohol-induced damage. It is suggested that inhibition of adult 
neurogenesis may be a factor that underlie alcohol-mediated cognitive dysfunction, which 
in turn may be a cause to decreased behavioral control over consumption (Nixon and 
McClain, 2010). Also, an influence of opioids and stimulant drugs on hippocampal 
neurogenesis in adults has been confirmed (Eisch et al., 2000). Exposure to psychotropic 
drugs is suggested to regulate the rate of neurogenesis in the adult brain, suggesting a 
possible role for neurogenesis in the drug-induced impairments seen in cognitive functions 
(Duman et al., 2001).  
This article is aimed to provide a comprehensive collocation of the impact of abusing drugs 
on cognitive functions. It describes adverse effects on learning and memory of selected 
drugs and how these compounds interact with neuronal circuits involved in these 
behaviors. Possible approaches to deal with these drug-induced damages from the 
pharmacological point of view will also be discussed.  
2. Memory and learning  
Memory is described as a multi-system phenomenon in the brain. Each system has been 
associated with a separate memory function targeting different neurological substrates. For 
example, declarative memory is attributed to a function of retaining conscious memories of 
facts and sights. The establishment of new declarative memories is related to structures in 
the diencephalon and the medial temporal lobe, and it has been proposed that these 
memory imprints are generated in specific areas of the cerebral cortex. For example, brain 
areas implicated in deficits in declarative memory include the prefrontal cortex and the 
hippocampus. The frontal cortex is recognized as an important substrate for features related 
to reasoning and memory content of the declarative memory (Samuelson, 2011; Weiss and 
Disterhoft, 2011). Classical conditioning, skill learning and repetition learning, i.e. 
nondeclarative forms of memory, are documented through changes in the way they are 
carried out and are not considered to involve conscious recollection. The functional anatomy 
of these nondeclarative forms of memory are believed to comprise the basal ganglia, 
cerebellum and  cerebral cortex. 
A concept of synaptic plasticity essential for the storage of long-term memory (LTM) at the 
cellular level is the long-term potentiation (LTP). LTP is shown to enhance the signal 
transmission between neighboring neurons over a long period of time and it can be induced 
by high-frequency stimulation of the synapse, and at this level it represents an important 
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target for studies of memory enhancement. LTP is an attractive candidate for explanation of 
cellular mechanisms underlying learning and memory as it shares many features with LTM. 
Both LTP and LTM are triggered rapidly, and each of them seems to be dependent on the 
biosynthetic process for protein formation and the proteins, which are formed, are belived 
to have a role in associative memory and have been suggested to last over a long period of 
time. Furthermore, LTP is found to be linked to a number of different types of learning, and 
these are shown to include the simple classical conditioning observed in experimental 
animals as well as the more complex, higher-level cognition that is experienced by humans 
(Cooke and Bliss, 2006). 
Although LTP is not demonstrated in all brain regions it has been clearly seen in many 
areas, including amygdala, hippocampus, nucleus accumbens and prefrontal cortex, i.e. 
regions involved in drug reward but also in memory and learning (Kenney and Gould, 
2008). For instance, enhanced activity in amygdala and enhanced amygdala-hippocampus 
connectivity leading to long-lasting, non-temporary memory alterations has been described 
(Edelson et al., 2011). It was further indicated that the hippocampus is essential for the 
transfer of short-term memories to LTMs (Santini et al., 2001; Glannon, 2006). In addition, 
clinical investigations including neuropsychological patients as well as studies using 
experimental animals have suggested that, in addition to its critical role in the LTM 
formation, the hippocampal structure is essential for the integrating and processing of 
spatial and coherent information (Kim and Lee, 2011). 
The molecular mechanism underlying memory potentiation is suggested to involve the 
excitatory amino acid glutamate (Abel and Lattal, 2001). Glutamate binding activates both 
the N-methyl-D-aspartyl (NMDA) and the α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) receptors located on the cell membrane of the nerve cells. These 
events lead to the opening of calcium and sodium channels into the nerve cells. The calcium 
influx activates the enzyme adenylate cyclase, which in turn converts ATP to cAMP. 
Subsequent to this event the cAMP actuates a sequential activation of protein kinase A, 
mitogen-activated protein kinase/extracellular signal-regulated protein kinase, as well as 
the cAMP response element-binding factor (CREB). The activated CREB attaches to DNA 
and induces transcription and subsequently an increased production of proteins essential 
for the construction of new synapses (Abel and Lattal, 2001). 
Regarding the NMDA receptor it has been shown in experimental animal models that the 
organization of the receptor subunits NR1, NR2A, NR2B and NR2D is essential for the 
memory promoting effect of glutamate. For instance, transgenic mice overexpressing the  
NR2B subunit exhibit improved performance in memory tests (Tang et al., 1999 ). Also the 
ratio of the NR2B to NR2A ratio has been shown as a relevant marker on cognitive 
functioning in the rat. Increased ratio of NR2B/NR2A has been seen to increase LTP (Le 
Grevès et al., 2002; Le Grevés et al., 2006; Zhao et al., 2005). 
A considerable amount of evidence supports an important role for glutamate and its ligand-
gated ionotropic receptors (i.e. NMDA, AMPA, and kainic acid (KA) subtypes) in mediating 
addictive behaviors have been collected over the years (Wolf, 1998; Tzschentke and Schmidt, 
2003; Kalivas, 2004;  Gass and Olive, 2009). However, the role of metabotropic glutamate 
(mGlu) receptors in the neural mechanisms underlying drug addiction has become apparent 
only within the latest decades (Olive, 2010). Evidence for a role of Group I (mGlu1 and 
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mGlu5) receptors in regulating drug intake, reward, reinforcement, and reinstatement of 
drug-seeking behavior have emerged from recent pharmacological and genetic studies 
(Olive, 2009) . However, these kind of mGlu receptors is also suggested to mediate cognitive 
processes including learning and memory, behavioral flexibility, and extinction 
(Moghaddam, 2004; Simonyi et al., 2005; Gravius et al., 2006; Gass and Olive, 2009) and 
deficits in these expressions of cognition are frequently observed in drug addicts. 
3. Drug effects on cognitive function  
As mentioned above drug addiction is seen as a chronic relapsing disorder with persistent 
brain alterations associated with cognitive, motivational and emotional alterations and 
studies have indicated the presence of extensive cognitive alterations in many individuals 
diagnosed with substance use disorders (Goldstein and Volkow, 2002; Fernández-Serrano et 
al., 2010). Thus, over the past decades the influence of abusing drugs on cognitive 
capabilities in addicts has been the subject for many studies in various clinical and basic 
science laboratories.  Although it has been known for long that alcoholism is connected with 
deficient memory and learning and seems to accelerate aging processes, negative effects of 
chronic use of narcotics on cognitive functions have become evident during more recent 
times. This section focuses on adverse effects induced by some frequently used drugs, 
including alcohol, central stimulants, and opioids. All these substances have been reported 
to affect many aspects of memory and learning. 
3.1 Alcohol-induced effects on memory and cognition 
Emerging data from past and current research provide evidence for cognitive impairments 
of alcohol-dependent patients, particularly regarding their ability to perform tasks sensitive 
to frontal lobe function. This fact has brought up the importance of a significant abstinence 
allowing individuals with these impairments to recover (Glass et al., 2009; Loeber et al., 
2009). 
The adverse effect of alcohol on cognitive function is typified by the well-known Wernicke-
Korsakoff syndrome (WKS). This disorder is a neurological disturbance and it is caused by 
the lack of thiamine (vitamin B1) in the brain. Its onset is linked to mal nutrition or to 
alcoholism. In Western countries WKS is perhaps the most common alcohol-induced 
memory disturbance. It is characterized by neuropathological changes in the diencephalon, 
including the anterior part of the thalamus, and the mammillary body caused by thiamine 
deficiency (Kopelman et al., 2009). The most characteristic neuropsychological feature of 
WKS is a marked decline in memory capabilities, whereas other intellectual abilities are 
relatively preserved. Alcohol-related dementia is generally defined as alcohol-induced 
dementia in the Diagnostic and Statistical Manual of Mental Disorders IV- Text Revision 
(DSM-IV- TR). It has been described as an organic brain syndrome induced by over-
consumption of alcohol, which causes severe cognitive impairment, including executive 
dysfunction, lack of emotional control and disturbances in memory function (Asada et al., 
2010). 
Evidence that emerges from experimental studies has shown that early exposure to alcohol 
sensitizes the neurocircuitry of addiction and affects chromatin remodeling. These events 
could give rise to altered plasticity in reward-related cognitive processes that contribute to 
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vulnerability to drug addiction in adolescents (Guerri and Pascual, 2010). There are 
potential mechanisms by which alcohol affects brain development and causes brain 
impairments including cognitive and behavioral dysfunctions but also neurochemical 
processes underlying the adolescent-specific vulnerability to drug addiction (Guerri and 
Pascual, 2010).  
Moreover, in heavy episodic drinkers reduced psychomotor speed and a decline in accuracy 
when performing tasks of attention, working memory, implicit memory as well as associate 
learning and memory have been reported (Cairney et al., 2007). For instance, among the 
population of Aboriginal Australians, who were heavy episodic alcoholic users, specific 
cognitive abnormalities that suggest frontostriatal abnormalities have been observed in 
association with chronic alcoholism (Cairney et al., 2007). 
In the brains of alcoholics the frontal lobes, with significant neuronal losses in the superior 
frontal cortex, are shown to be the most insulted areas (Kubota et al., 2001; Sullivan and 
Pfefferbaum, 2005). These lobes are known to regulate complex cognitive skills including 
working memory, attention, temporal ordering, mood, motivation, risk taking and wanting 
as well as discrimination and reversal learning that underlie judgment. Studies have 
revealed that a complicated mechanism may underlie alcohol-induced damage to the brain. 
Also, the mechanism underlying the abstinence-induced regeneration seems to be complex. 
The magnitude of neurodegeneration and the potential for recovery and regeneration vary 
between different regions of the brain and seem to be dependent on several factors, such as 
pattern of intake, age and genetics (Crews and Nixon, 2009). Moreover, binge ethanol 
exposure of rats is seen to reduce hippocampal neurogenesis (Nixon and Crews, 2002) and 
brain degeneration in the binge ethanol treatment model is generally widely circulated and 
diffused, in similarity to what is observed in human alcoholics.  
A recent study performed in order to investigate the harmful effects of binge alcohol on the 
hippocampal neurogenesis in adolescent non-human primates suggested that the liquid 
drug may interfere with the migration and distribution of hippocampal preneuronal 
progenitors (Taffe et al., 2010). Furthermore, the decreased neurogenesis induced by alcohol 
in the hippocampus was seen to be paralleled by an increase in neural degeneration thought 
to be mediated by non-apoptotic pathways. This effect remained for quite a long time 
following alcohol discontinuation and it was suggested to cause the deterioration in 
hippocampus-associated cognitive tasks that are frequently seen in alcoholics (Taffe et al., 
2010). 
Regarding the mechanism underlying alcohol-induced neurodegeneration and cognitive 
impairment the involvement of glutamatergic neurotransmission seems well documented, 
however, many details of the underlying mechanism remains unknown. Studies have been 
focused both on the NMDA receptor system and the group II metabotropic glutamate 
receptor.  A recent study examined the effect of the agonist LY379268 on its ability to 
prevent neuronal death and learning deficits in a rat model of binge-like exposure to alcohol 
(Cippitelli et al., 2010). It was found that neurodegeneration was most extensive in the 
ventral hippocampus and the entorhinal cortex (EC) and the glutamate receptor agonist was 
potently neuroprotective in the EC but not in the dentate gyrus of the hippocampus. In 
additional experiments, binge alcohol exposure suppressed the expression of transforming 
growth factor beta (TGF-beta) expression in both the EC and dentate gyrus, while the 
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glutamate agonist increased TGF-beta in the EC only. It was further reported that the 
neuroprotective effects of the glutamate agonist were paralleled with prevention of deficits 
in spatial reversal learning. These data was considered to give support for a protective role 
of TGF-beta and group II metabotropic glutamate receptor agonists in alcohol-induced 
neurodegeneration (Cippitelli et al., 2010). 
However, studies have confirmed that alcohol may damage specific regions both in the 
adult and the adolescent brain (Alfonso-Loeches and Guerri, 2011).  The mechanisms behind 
this damage is suggested to involve excitotoxicity, free radical formation and 
neuroinflammatory destructions caused by activation of the immune system and mediated 
through Toll-like receptor 4 (TLR4 receptor). Alcohol is also shown to act on specific cell 
surface receptors, e.g. the NMDA, GABA-A receptors and on certain ion channels, like L-
type Ca²+ channels and GIRKs but the drug is also found to interact with various signaling 
pathways, e.g. PKA and PKC signaling. All these multi-targets are belived to underlie the 
wide variety of behavioral effects seen to result from chronic intake of ethanol (Alfonso-
Loeches and Guerri, 2011). 
Several effects of alcohol seems to involve the endogenous opioid systems (EOS). Opioid 
peptides, including beta-endorphin, have a role in mediating the reward effect of the 
drug. However, also  some adverse effects are mediated through the EOS. A recent study 
on human alcohol-dependent subjects investigated whether the EOS is altered in brain 
areas involved in cognitive control of addiction. Human post-mortem brain specimens, 
including the dorsolateral prefrontal cortex (dl-PFC), orbitofrontal cortex (OFC) and 
hippocampus, from alcoholic and control subjects were examined. The expression of the 
prodynorphin gene transcript and dynorphin peptides in dl-PFC, the κ-opioid peptide 
(KOP) receptor message in OFC and dynorphins in hippocampus were all up-regulated in 
alcoholics. No significant changes in expression of other EOS gene transcripts were 
reported. Activation of the KOP receptor by the up-regulated dynorphin peptides in 
alcoholic brains was suggested to at least partly underlie neurocognitive dysfunctions 
relevant for addiction and disrupted inhibitory control (Bazov et al., 2011). In a 
subsequent study  focused on genetic, epigenetic and environmental factors and their 
influence on the risk for alcoholism the result was indicative of a causal link between 
alcoholism-associated prodynorphin 3'-UTR CpG-SNP methylation, activation of 
prodynorphin transcription and vulnerability of individuals with the C, non-risk allele(s) 
to develop alcohol dependence (Taqi et al., 2011). 
A study highlighting the specific attentional processes impaired in alcoholics concluded 
that a representative sample of alcoholics show specific deficits of attention as opposed to 
a general decline of attention at treatment intake. It was thus reported that sober 
alcoholics appear to be as efficient as controls at selecting on the basis of location, 
however, when they are required to select on the basis of semantic information or 
required to respond to two independent sources of information they are at a deficit 
(Tedstone and Coyle, 2004).  
Taking together it appears that chronic alcohol intake under a variety of condiditions 
impairs cognitive factors including various aspects of memory and learning, attention, risk 
taking, motivation, mood and wanting. Specific brain areas targeted by the drug in this 
context includes hippocampus and frontal cortex. The mechanisms underlying the effects of 
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ethanol involve inhibition of neurogenesis and interaction with a number of signal 
pathways, including glutamate, monoamines and endogenous opioids. 
3.2 Effects of central stimulants on cognition 
Epidemiological studies have confirmed a high prevalence of stimulant drugs and that these 
drugs are being used increasingly over the past decades (Gonzales et al., 2010; Ciccarone, 
2011;  Vardakou et al., 2011). They have been taken in order to enhance social or cognitive 
performance but also to induce euphoria and wellbeing. However, chronic use of these 
drugs has been associated with substantial deficits in learning and verbal memory. Thus the 
harmful consequences of long-term stimulant abuse also seem to include neurodegenerative 
effects leading to cognitive disabilities (Ciccarone, 2011; McKetin and Mattik, 1997; 
Krasnova et al., 2005). 
3.2.1 Amphetamine 
The psychostimulant amphetamine is shown to improve cognition in healthy subjects but 
also in attention-deficit hyperactivity disorder as well as in other neuropsychiatric disorders. 
However, at higher doses the stimulant may induce impaired cognitive function (Reske et 
al., 2010), particularly those mediated by the prefrontal cortex (Xu et al., 2010). Also, chronic 
use of amphetamine induces significantly impaired performance in cognitive tests (Ornstein 
et al., 2000). Data has indicated that amphetamine as well as other psychostimulants affects 
the capacity of the brain to stimulate neurogenesis, and that their effects also include 
disruption of the blood-brain barrier (BBB) (Silva et al., 2010). Thus, in chronic use the 
psychostimulatory effect of amphetamine is not only connected with reward and euphoria 
but also with impairments in attention and memory. These cognitive deficits have been 
suggested to be related to neurotoxic effects of the drug (Krasnova et al., 2005). 
Amphetamine injection is shown to affect dopaminergic terminals in striatal cells and to 
increase levels of cleaved caspase-3, a marker of apoptosis. Furthermore, the stimunlant is  
also demonstrated to increase the expression of p53 and Bax at both transcriptional and 
protein levels, whereas it decreased the levels of the Bcl-2 protein, all these events in 
agreement with increased apopotosis (Krasonova et al., 2005). Amphetamine is also shown 
to affect dopamine circuits in the prefrontal cortex (Dunn and Killcross, 2007; Fletcher et al., 
2007) and thereby inducing impaired cognitive function. 
3.2.2 Cocaine 
Long-lasting memory deficits have been seen in individuals chronically abused to cocaine 
(Beatty et al., 1995; Bolla et al., 1999), although some ambiguities in respect to the specificity 
of this impairment remain to be fully clarified. Also, in studies using preclinical models of 
addiction it was demonstrated that stress and mechanisms related to the HPA-axis may 
contribute to impaired learning (Ehninger and Kempermann, 2006). In a more recent study 
it was shown that the deficiences in learning and memory seen in individuals addicted to 
cocaine are associated with increased levels of cortisol but also with the outcomes of cocaine 
use after inpatient treatment (Fox et al., 2009). Learning-related deficits was found to include 
poor immediate and retardent verbal recall and recognition as well as a selective reduction 
in working memory. These findings were seen to be in congruence with studies implicating 
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that neuroadaptations in cocaine addicts affects learning and memory function, which in 
turn, appeared to affect the outcomes of drug use (Fox et al., 2009).  
Sudai and collaborators investigated the effects of cocaine on cell proliferation and 
neurogenesis in the hippocampal dentate gyrus of adult rats (Sudai et al., 2011). The 
influence of the stimulant drug on working memory during abstinence was examined using 
the water T-maze test. Results suggested that cocaine, in addition to its effects on the reward 
system, also may inhibit the generation and development of new cells in the hippocampus, 
and thereby reduce the capacity of the working memory (Sudai et al., 2011). 
In studies on mechanisms underlying the effects of cocaine on memory function several 
laboratories have focused on brain circuits and transmitter substances known to be involved 
in stress and memory formation. Muriach and collaborators described a study on nuclear 
factor kappa B (NFKappaB). NFKappaB is known as a sensor of oxidative stress and it is 
demonstrated to have a role in memory formation that could be involved in addiction 
mechanisms. They reported a mechanistic role of NFKappaB in alterations induced by 
cocaine and observed memory disabilities that was impaired and correlated negatively with 
the NFkappaB activity in the frontal cortex (Muriach et al., 2010). Cocaine has also been 
shown to induce neuroadaptive effects in hippocampal regions by enhancing LTP through 
interaction with the dopamine transporter and a subsequent enhancement of dopamine 
(Thomson et al., 2005). Subsequent studies have confirmed that endogenous dopamine in 
the presence of cocaine facilitates the elevation of basal hippopcampal LTP (Stramiello and 
Wagner, 2010). Cocaine may also induce impairments in working memory by action on 
dopaminergic circuits in the prefrontal cortex (George et al., 2008). 
3.2.3 Methamphetamine, ecstasy and mephedrone 
In addition to amphetamine, during the past years chronic use of several stimulant drugs 
with similar structure have been shown to impair cognitive functions. Among these 
compounds are methamphetamine, ecstasy and perhaps also cathinones (Gouzoulis-
Mayfrank and Daumann, 2009; Rogers et al., 2009; Hoffman and Al'Absi, 2010). All these 
substances are not in clinical use and are classified as illegal drugs. They are easily accessible 
at internet and are misused in many countries. Regarding their mechanism of action ecstasy 
was shown to cause selective and persistent damages on central serotonergic nerve 
terminals, while methamphetamine produces lesions in both the serotonergic and 
dopaminergic systems. Also mephedrone seems to affect both transmitter systems (Kehr et 
al., 2011). 
Chronic methamphetamine is shown to cause persisting cognitive deficits in human addicts 
as well as in animals exposed to this central stimulant (Reichel et al., 2011). Recent findings 
suggest that methamphetamine may induce a hypofunction in cortical areas that are 
important for executive function that in turn underlies the cognitive control deficits seen in 
individuals dependent on this drug (Nestor et al., 2011).  
Methamphetamine-induced changes in the serotonin transporter SERT function in areas 
associated with cognition  may underlie memory deficits independently of overt neurotoxic 
effects (Reichel et al., 2011). Moreover, data has indicated that also the σ receptors may be 
implicated in various acute and subchronic effects of methamphetamine. These include 
locomotor stimulation, development of sensitization and neurotoxicity, effects that may be 
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attenuated by σ receptor antagonists. The σ receptors are also suggested to be involved in 
methamphetamine-induced deficits in cognitive and motor function (Kaushal and 
Masumoto, 2011).  
Abuse of methamphetamine has also been seen to result in impaired adult hippocampal 
neurogenesis, and effects of this stimulant drug on neural progenitor cells is suggested to be 
mediated by protein nitration (Venkatesan et al., 2011). This observation was considered to 
open for new strategies regarding design and development of therapeutic approaches for 
methamphetamine-abusing individuals with neurologic dysfunction or even for other 
disorders with impaired hippocampal neurogenesis. 
Use of ecstasy is shown to reduce cognitive functioning by reducing levels of dopamine and 
serotonin in CNS areas of importance for memory and learning (Gouzoulis-Mayfrank and 
Daumann, 2009; Chummun et al., 2011). Ecstasy is an abusing drug related to amphetamine 
and can act as a stimulant producing euphoria by enhancing dopamine levels in the nucleus 
accumbens in conformity to but to a lesser extent than amphetamine and cocaine. However, 
ecstasy may also interact with serotonergic payhways and long term exposure to this drug 
results in decreased activity in both serotonin and dopamine neurons (Kehr et al., 2011). The 
reduction in these transmitter systems is seen as dose-related impairments in cognitive 
function, in particular regarding  complex cognitive skills. The decreased serotonergic and 
dopaminergic activity is also believed to cause changes in mood, hallucinations, altered 
perception and memory loss. Previous and current research demonstrate that abusing 
ecstasy is strongly associated with deteriorated working memory, and that this worsening 
correlates to the total lifetime of ecstasy consumption. These findings stresses the long-term, 
cumulative behavioral manifestations linked to ecstasy use in humans (Nulsen et al., 2010). 
Ecstasy users often show decreased levels of serotonin, its metabolite 5-HIAA, tryptophan 
hydroxylase and SERT density during abstinence. They also display functional impairments 
in learning and memory but also in higher cognitive processing, as well as sleep disturbance 
and deficits related appetite and reduced psychiatric wellbeing (Canales, 2010). These 
psychobiological impairments appeared most pronounced in heavy ecstasy users and may 
reflect losses in serotonergic axones in certain brain regions, in particular the frontal lobes, 
temporal lobes and hippocampus. These complications seem to last long after cessation of 
ecstasy use, suggesting that these drug-induced neurological impairments may be 
permament. It is believed that at least some of the harmful effects on memory of ecstasy 
abuse could result from its neurotoxic actions on adult hippocampal neurogenesis. Evidence 
suggests that stimulant abuse negatively affects cognitive functions that are regulated and 
influenced by adult hippocampal neurogenesis, including contextual memory, spatial 
memory, working memory and cognitive flexibility (Canales, 2010). 
4-methylmethcathinone (mephedrone) represents a designer stimulant that is among the 
most popular of the naturally occurring psychostimulant cathinone derivatives. A web- 
based survey has shown that mephedrone users consider the effects of this drug to compare 
best with those of ecstasy (Carhart-Harris et al., 2011), which agrees with research studies 
comparing the effects of mephedrone and ecstasy on brain 5HT and dopamine (Kehr et al., 
2011). This cathinone has been readily available for purchase both online and in the streets 
and has been promoted by aggressive web-based marketing. Its abuse in many western 
countries has been described as a serious public health concern (Hadlock et al., 2011). In 
conformity with ecstasy, metamphetamine and methcathinone, repeated mephedrone 
www.intechopen.com
 
Brain Damage – Bridging Between Basic Research and Clinics 230 
injections causes a rapid decrease in the striatal dopamine and in the hippocampal 5HT 
transporter function. Mephedrone is also shown to inhibit both synaptosomal dopamine 
and 5HT reuptake. Similar to ecstasy but unlike methamphetamine or methcathinone, 
repeated mephedrone also causes persistent serotonergic, but not dopaminergic, deficits 
(Hadlock et al., 2011, Kehr et al., 2011). No studies on learning and memory impairments in 
mephedrone abusers has yet been published, however, due to similarieties with ecstasy and 
methamphetamine research investigating the actual domains of cognition in chronic and 
abstinent mephedrone users seems to be warranted in the future. 
4. Opioid-induced adverse effects on cognitive functions 
A variety of neuropathologic adaptations have been detected in the brains of heroin addicts. 
These include pathology caused by bacterial infections, viral infections, such as HIV-1 
infection, but also complications such as hypoxic–ischemic encephalopathy with cerebral 
edema, ischemic neuronal damage and neuronal loss (Büttner et al., 2000). However, chronic 
exposure to opiates, such as heroin, morphine and to some extent also methadone are 
shown to impair cognitive function (Mintzer and Stiltzer, 2002; Gruber et al., 2007; Soyka et 
al., 2011). Heroin is characterized as one of the most frequently abused illegal drugs, and 
addiction to this drug is linked to significant attention deficits and inadequate performance 
on memory tasks (Guerra et al., 1987). Furthermore, chronic exposure to morphine is also 
shown to cause vigilance and attention impairments in chronic pain patients (Mao et al., 
2002) and impairs acquisition of reference memory in rats (Spain and Newsom, 1991; Lu et 
al., 2010). Also addicts in methadone maintenance programs or chronic pain patients treated 
with methadone are shown to display cognitive impairmats (Mitzler and Stitzer, 2002; 
Soyka et al., 2010).  These findings suggest an effect of chronic opiates on brain regions 
related to learning and memory, such as the frontal cortex (Ornstein et al., 2000; Yang et al., 
2009) and the hippocampus (Lu et al., 2010) 
Regarding the mechanisms by which opioids induce cognitive impairments through action 
on hippocampal and prefrontal cortex structures it is shown that these drugs may enhance 
apoptosis and inhibted neurogenesis. An opioid-induced attenuation of neurogenesis in 
hippocampus was earlier seen in male rats exposed to morphine (Eisch et al., 2000). Thus, 
opiates, such as morphine, is seen to reduce neurogenesis in the adult hippocampal 
subgranular zone (SGZ), suggesting that a waning neurogenesis contributes to opioid-
induced deficits in cognitive function (Arguello et al., 2008). Enhanced apoptosis following 
exposure to opioids was reported to involve an upregulation of the proapoptotic caspase-3 
and Bax proteins following NMDA receptor activation (Mao et al., 2002). Also, chronic 
methadone have been shown to up-regulate several pro-apoptotic proteins in the cortex and 
hippocampus, indicating activation of both the NMDA-receptor and mitochondrial 
apoptotic pathways (Tramullas et al., 2007). In addition, morphine-induced expression of 
the Toll-like receptor 9 (TLR9) and microglia apoptosis was suggested to involve the  μ-
opioid peptide receptor, MOP (He et al., 2011). It was further suggested that inhibition of  
the TLR9 and/or blockage of the MOP receptor may be a possible route for preventing 
opioid-induced brain damage. 
The opiate elicited apoptosis in human fetal microglia and neurons (Hu et al., 2002), was 
also associated with morphine tolerance (Mao et al., 2002). The apoptotic effect of morphine 
is blocked by the opioid receptor antagonist naloxone (Hu et al., 2002), indicating an opioid 
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receptor mechanism involved in this effect. The effect of morphine is known to be mediated 
mainly through the MOP receptor although, at high concentrations, this opiate is known 
also to interact with both the delta-opioid peptide (DOP) and the KOP receptors. 
Furthermore, it appears that the opioid receptor subtypes (MOP, DOP, and KOP) may 
regulate different aspects of neuronal development (Hauser et al., 2000). Evidence 
suggesting that the MOP receptor could play an important role in regulating progenitor cell 
survival has recently been described (Harburg et al., 2007). In addition, morphine was 
earlier shown to promote anomal programmed cell death by increasing the expression of the 
proapoptotic Fas receptor protein and decreasing the expression of the antiapoptotic Bcl-2 
oncoprotein by maintaining the activation of opioid receptors (Boronat et al., 2001). Studies 
also indicated that opiate-induced alteration of hippocampal function most likely results 
from inhibited neurogenesis (Eisch and Harburg, 2006). 
5. Reversal of drug-induced impairments of abusing drugs 
It is obvious from the above that chronic use of many addictive drugs may elicit pronounced 
effects on brain structures associated with cognitive functions leading to impaired learning 
and memory capabilities. It is not yet clarified whether the effects are reversible or persist 
over the life time. However, it seems that for many individual addicts these drug-induced 
damages may contribute to accelerated senescence. Many attempts to develop therapeutic 
strategies to deal with this complication have been reported. Indeed, attempts to design 
molecules that may counteract these deficits and enhance cognitive capabilities have been 
reported over the past decade. Several approaches to reverse cognitive impairmnts induced 
by central stimulanta have been reported. In the following this article will describe attempts 
to reverse morphine-induced damage in the hippocampus with the far aim to reconstitute 
cognitive abilities in experimental animals exposed to opioids. 
5.1 Attempts to reverse of opioid-induced impairments on cognition 
In a previous study we demonstrated that a single dose of morphine may affect the expression 
of the growth hormone (GH) receptor as well as the GH binding protein (GHBP) in the rat 
hippocampus. The gene transcripts were significantly attenuated 4 h following drug injection 
but was restored after 24 h (Thörnwall-LeGreves et al., 2001). In rats chronically treated with 
morphine, a decrease in GH binding was observed during the acute phase but this alteration 
was restored when animals were tolerant to the drug (Zhai et al., 1995). 
As mentioned above, chronic morphine may reduce neurogenesis in the granule cell layer of 
hippocampus in the adult rat and a similar effect was seen in male rats after chronic self-
administration of heroin (Eisch et al., 2000). Furthermore, studies have shown that opioid 
effects on nerve cell regeneration is not mediated through interactions with the HPA-axis, as 
similar effects were found also in rats subjected to adrenalectomy and subsequent 
corticosterone replacement. These observations suggest that the opioid regulation of 
neurogenesis in the adult rat hippocampus may be mediated by direct effects of the opioid 
drugs on the hippocampal function. The recent study by Arguello and co-workers, as 
mentioned above, demonstrated that chronic morphine attenuates neurogenesis in the SGZ 
by impeding cell-dividing, primarily in the S-phase, and inhibiting progenitor cell 
progression to a more mature stage (Arguello et al., 2008). In order to find strategies to 
reverse the opioid-induced damage to the hippocampal function it is essential to look for 
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agents that may stimulate hippocampal progenitors and thereby increase neurogenesis and 
regeneration of nerve cells. The above mentioned opioid effects on GH and its receptor 
suggest that the somatotrophic axis may be of importance in this regard. Indeed, both GH 
and its mediator insulin-like growth factor-I (IGF-I) have been reported to induce 
neuroprotective effects and also stimulate neurogenesis (Isgaard et al., 2007; Nyberg, 2009). 
5.1.1 The impact of the somatotrophic axis on neuroprotection  
Data indicating a substantial impact of the somatotrophic axis on nerve cell regeneration has 
been reported (Isgaard et al., 2007). IGF-I treatment was found to promote cell genesis in the 
brains of adult GH- and IGF-1-deficient rodents (Anderson et al., 2002; Aberg et al, 2009). In 
the hippocampus, treatment with bovine GH (bGH) induced an increase in the number of 
BrdU/NeuN-positive cells proportionally to the recorded increase in the number of BrdU-
positive cells. In vitro incorporation of 3[H]-labeled thymidine demonstrated that short-time 
exposure to bGH enhanced the cell proliferation in adult hippocampal progenitor cells. This 
observation demonstrated that peripherally administrated GH may increase the number of 
new cells in the brain of adult rats and that the hormone may exert a direct proliferative 
effect on neuronal progenitor cells (Aberg et al., 2006; Aberg et al., 2009).  
Positive effects of GH on neurogenesis have been observed in several laboratories. A study 
by Harvey and co-workers showed that the hormone is produced in the retinal ganglion 
cells of embryonic chicks, in which GH stimulates cell survival during neurogenesis. The 
mechanism underlying this action was investigated in neural retina explants collected from 
6-8 days-old embryos. These explants were allowed to incubate with GH for some days and 
the hormone was seen to reduce the number of spontaneous apoptotic cells. This anti-
apoptotic action of the hormone was accompanied by a reduction in the expression of the 
apoptotic marker caspase-3 but also by a reduced expression of the caspase independent 
apoptosis inducing factor-1. These actions were considered specific, since other constituents 
known to be involved in apoptotic signaling, such as bcl-2, bcl-x and bid, remained 
unaffected. The result from this study was suggested to indicate that GH-induced retinal cell 
survival involved pathways dependent and independent on caspase activity (Harvey et al., 
2006). 
Studies over the past decades have clearly demonstrated that GH targets many areas of the 
CNS (for reviews, see Nyberg, 2000; 2007), and that GH deficits has been associated with 
cognitive impairments, memory loss, as well as diminished well being (Bengtsson et al., 
1993: Burman and Deijen, 1998). GH replacement therapy in GH-deficient patients was 
demonstrated to ameliorate several adverse symptoms seen in these patients  (Bengtsson et 
al., 1993: Burman and Deijen, 1998; McMillan et al., 2003). The hormone was also found to 
prevent neuronal loss in the aged rat hippocampus, confirming a neuroprotective effect of 
GH in old animals (Azcoitia et al, 2005). Decreased levels of circulating GH with age (van 
Dam et al., 2002) declining density of GH-binding sites with aging was found in several 
areas of the human brain, including the hippocampus (Lai et al., 1993). GH was also seen to 
enhance the expression of the rat hippocampal gene transcript of the NMDA receptor 
subunit NR2B (Le Greves et al., 2002). This receptor subunit is known to enhance memory 
and cognitive capabilities in an age-dependent manner while overexpressed (Tang et al., 
1999). In addition, studies showed that GH replacement in hypophysectomized male rats 
may improve spatial performance and increase the hippocampal gene transcript levels of 
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some of the NMDA receptor subunits as well as the postsynaptic density protein 95  
(Le Greves et al., 2006; 2011). All together, these observations were considered to indicate a 
link between decreased GH levels in elderly and deterioration of cognitive functions, with a 
clear indication that the hormone may improve memory and cognitive capabilities and this 
may be compatible with increased neurogenesis as a result of GH administration. 
The mechanism by which GH induces its beneficial effects on memory and cognition is 
still not clarified in all its details. However, GH is shown to promote nerve cell 
regeneration as well as gliogenesis during the development of the fetal rat brain (Ajo et 
al., 2003), presumably through local production of IGF-1. Peripheral administrated GH 
reaching the CNS may induce a release of IGF-1 in the brain and this factor may in turn 
account for the mediation of brain effects of GH. However, local production of  both GH 
and IGF-1 in certain areas of the brain has been suggested, as mice with decreased levels 
of circulating GH and IGF-1 exhibit normal levels of the corresponding gene transcripts in 
the hippocampus (Sun et al., 2005). Also, GH is shown to be produced in the hippocampal 
formation, where it is suggested to be involved in functions associated with his region, 
such as learning and response to stress (Donahue et al., 2006). Effects on these behaviors 
may be caused by the action of GH-induced release of IGF-1 as this mediator is also 
shown to affect hippocampal related behaviors. In fact, intracerebroventricular 
administration of IGF-1 was found to attenuate the age-related decline in hippocampal 
neurogenesis in rats (Lichtenwalner et al., 2001). Moreover, peripheral infusions of IGF-1 
were seen to induce neurogenesis in the hippocampus of the adult rat (Aberg et al., 2000) 
and overexpression of IGF-1 promotes neurogenesis during the postnatal development 
(O’Kusky et al., 2000).  
5.1.2 Reversal of opioid-induced impairments by growth hormone 
In addition, a recent study showed that chronic morphine significantly and dose-
dependently attenuates neuronal cell density in cultured hippocampal cells from murine 
fetus (Svensson et al., 2008). The ability of morphine as well as other opioids to inhibit cell 
growth and induce apoptosis is already known from previous work as described earlier in 
this section (see section 4). Therefore, the decline observed in neurite outgrowth in the 
mouse hippocampal primary cell cultures (Nyberg, 2009; Svensson et al., 2008) was 
expected, and a consequence of this decline should be that markers of apoptosis, such as 
lactate dehydrogenase (LDH) and caspase-3, will be affected. In fact, the activity and level of 
these enzymes were found to be significantly enhanced (Svensson et al., 2008). The 
enhanced activity of LDH in morphine-treated hippocampal cells strongly indicates that 
morphine may induce apoptosis in cells of this brain area. LDH, a mitochondrial 
dehydrogenase, is known to represent a critical component of the astrocyte–neuron lactate 
shuttle. It regulates the formation of lactate and influences its turnover within the cells. 
Caspase-3 is another enzyme that serves as a marker of apoptosis and cleaved caspase-3 
represents an activated form of this enzyme that acts as a lethal protease at the most distal 
stage of the apoptotic pathway (Kuribayashi et al., 2006). This enzyme was also investigated 
in order to clarify whether the reduction seen in the hippocampal cell density involves 
elements related to apoptosis. It was noted that the level of cleaved caspase-3,  measured by 
Western blot analysis, was significantly enhanced by chronic morphine (Svensson et al., 
2008). 
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As noted above, the hippocampus represents a brain area localized within the limbic system 
and is well known as an important brain substrate required for the acquisition of declarative 
or explicit memory (Benfenati, 2007). From the literature cited above, it is evident that 
chronic administration of opiates may counteract cell growth and stimulate apoptosis, but it 
is also demonstrated that opiate-induced toxicity may include impaired neurogensis 
(Hauser et al., 2000; He et al., 2002; Mao et al., 2002; Eisch and Harburg, 2006). An impact of 
adult-generated neurons on learning and memory was earlier suggested as training on 
associative learning tasks was found to double these neurons in the rat brain dentate gyrus 
(Kenney and Gould, 2008; Gould, 2010). Consequently, memory dysfunctions induced by 
chronic exposure to opiates could result from decreased adult neurogenesis as these drugs 
may inhibit neurogenesis in the adult hippocampus (Eisch and Harburg, 2006; Eisch et al., 
2000). This inhibition might well reflect a decreased number of neural precursors caused by 
increased apoptosis of the newborn neurons. However, in recent years, several factors that 
may promote and enhance neurogenesis from preexisting neuronal precursors have been 
reported. Among them are GH and its mediator IGF-1 in addition to several other growth 
factors. IGF-1 is shown to be essential for hippocampal neurogenesis (Aberg et al., 2000, 
2006). As mentioned above, this factor is regulated through the somatotrophic axis, where 
GH has an important role as an activator and releaser of IGF-1 as well as its binding 
proteins.  
In order to investigate whether GH may reverse opiate-induced apoptosis or inhibition of 
neurogenesis, we examined the effect of human GH on murine primary hippocampal 
neuronal cell cultures exposed to morphine (Svensson et al., 2008).  We observed that GH 
could significantly reverse the morphine-induced inhibition of neurite outgrowth and that 
cell density was restored after treatment with the hormone. The effect of GH was evident 
both when the hormone was added with morphine and when it was added after the opiate 
had induced its damaging effect. We also noted that GH reversed the morphine-induced 
effects on the apoptopic markers LDH and caspase-3 activity (Svensson et al., 2008). Thus, 
combining these observations with the effects of GH seen on memory and spatial 
performance in rats (Le Greves et al., 2006,; 2011) it appears that the hormone may be useful 
for the reversal of the adverse effects of morphine or other opiates on brain cells. 
These data opens for future attemps also to use IGF-1 in order to reverse opioid-induced 
damage on the brain to improve cognitive capabilities. It also opens for the possibility to 
stimulate the somatotrophic axis to reverse cognitive impairments induced by other drugs 
of abuse. Actually, as can be seen below, growth factors have been used in attempt to 
counteract brain damages induced by alcohol. 
5.2 Attempts to reverse alcohol-induced impairments in cognition 
Studies on the reversal of the adverse effects induced by various drugs have shown that 
certain growth factors may be useful in attempts to counteract drug-induced cell damage 
and apoptosis. For instance, it was demonstrated (Gibson et al. 2002) that stimulation of 
human embryonic kidney cells HEK 293 and the breast cancer cell line MDA MB 231 with 
epidermal growth factor (EGF) effectively and dose-dependently protected these cells from 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. This 
stimulatory effect was shown to reduce apoptosis by blocking both TRAIL-mediated 
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mitochondrial release of cytochrome c and activation of caspase-3. It was further shown that 
the survival response of EGF involved the activation of the protein kinase Akt. Activation of 
Akt was found to be sufficient for inibition of the TRAIL-induced apoptosis, and the 
expression of kinase-inactive Akt abolished the protective effect of EGF. In contrast, 
inhibition of the stimulatory effect of EGF on the extracellular-regulated kinase (ERK) 
activity did not affect EGF protection. From these findings it was concluded that activation 
of the EGF receptor generates a survival response against TRAIL-induced apoptosis by 
blocking the release of cytochrome c from the mitochondria, which, in turn, is mediated by 
the activation of Akt in epithelial-derived cells.  
The effects of estrogens and certain growth factors subsequent to ethanol treatment were 
recently examined in order to assess the potential of these hormones to reverse the effects of 
ethanol-induced damage (Barclay et al., 2005). The result of these studies indicated that both 
IGF-I and bovine basic fibroblast growth factor (bFGF) reduced toxic effect of the drug on 
neuronal survival, whereas estrogen, bFGF, and nerve growth factor (NGF) seemed to 
increase the total neurite length after ethanol treatment (Barclay et al., 2005). In addition, 
heparin-binding epidermal growth factor (HB-EGF), also a member of the EGF family of 
growth factors, has been reported to prevent apoptosis and differentiation and, in a very 
recent study, it was shown that stimulation with HB-EGF could reverse alcohol-induced 
apoptosis in human embryonic stem cells (Nash et al., 2009). Another possibility for 
reversing alcohol-induced cell damage involves brain-derived neurotrophic factor (BDNF). 
BDNF signaling plays an important role in neural survival and differentiation and studies 
have shown that alcohol significantly reduces BDNF signaling in neuronal cells (Climent et 
al., 2002). Also, the antiproliferative action of ethanol can be modulated by changing the 
sensitivity of the autophosphorylation of the IGF-1 receptor to ethanol (Seiler et al., 2000). 
This raised the question of whether IGF-1 could counteract the antiproliferative effects 
induced by alcohol. In fact, studies have shown that alcohol inhibits differentiation of the 
neural stem and that this effect is reduced by both IGF-1 and BDNF (Tateno et al., 2004). 
These results suggest the possibility that stimulation of neurotrophic factor signaling can 
reverse apoptosis induced by alcohol exposure. 
6. Conclusions  
It is evident from studies reviewed in this article that most drugs of abuse may induce 
adverse effects on brain structures associated with cognitive functions. In most cases these 
effects seem to impact brain circuits linked to important aspects of cognition, such as 
memory and learning, attention, risk taking, motivation, mood and wanting. The deficits 
induced on these behaviors by alcohol and opioids are well documented, whereas those of 
central stimulants and other abusing drugs are less well characterized. As mentioned in this 
article an important issue is the approach to find strategies to reverse the drug-induced 
deficits and in the case of damages induced by alcohol and opioid abuse it seems that 
certain growth factors may be useful and open for new methods for successful therapy. 
7. Acknowledgment  
This work was supported by the Swedish Medical Research Council (Grant 9459) and by  
the Swedish Council for Working Life and Social Research.  
www.intechopen.com
 
Brain Damage – Bridging Between Basic Research and Clinics 236 
8. References  
Abel T, Lattal KM (2001). Molecular mechanisms of memory acquisition, consolidation and 
retrieval. Curr Opin Neurobiol. 11:180-187. Review. 
Aberg MA, Aberg ND, Hedbäcker H, Oscarsson J, Eriksson PS (2000). Peripheral infusion of 
IGF-I selectively induces neurogenesis in the adult rat hippocampus. J Neurosci. 
20:2896-2903. 
Aberg ND, Brywe KG, Isgaard J (2006). Aspects of growth hormone and insulin-like growth 
factor-I related to neuroprotection, regeneration, and functional plasticity in the 
adult brain. ScientificWorld Journal. 6:53-80. 
Aberg ND, Johansson I, Aberg MA, Lind J, Johansson UE, Cooper-Kuhn CM, Kuhn HG, 
Isgaard J (2009). Peripheral administration of GH induces cell proliferation in the 
brain of adult hypophysectomized rats. J Endocrinol. 201:141-150. 
Ajo R, Cacicedo L, Navarro C, Sanchez-Franco F (2003). Growth hormone action on 
proliferation and differentiation of cerebral cortical cells from fetal rat. 
Endocrinology. 144:1086-1097. 
Alfonso-Loeches S, Guerri C (2011). Molecular and behavioral aspects of the actions of 
alcohol on the adult and developing brain. Crit Rev Clin Lab Sci. 48:19-47.  
Anderson MF, Aberg MA, Nilsson M, Eriksson PS (2002). Insulin-like growth factor-I and 
neurogenesis in the adult mammalian brain. Brain Res Dev Brain Res. 134:115- 122. 
Arguello AA, Harburg GC, Schonborn JR, Mandyam CD, Yamaguchi M, Eisch AJ (2008). 
Time course of morphine's effects on adult hippocampal subgranular zone reveals 
preferential inhibition of cells in S phase of the cell cycle and a subpopulation of 
immature neurons. Neuroscience. 157:70-79. 
Asada T, Takaya S, Takayama Y, Yamauchi H, Hashikawa K, Fukuyama H (2010). 
Reversible alcohol-related dementia: a five-year follow-up study using FDG-PET 
and neuropsychological tests. Intern Med. 49:283-287. 
Azcoitia I, Perez-Martin M, Salazar V, Castillo C, Ariznavarreta C, Garcia-Segura LM, 
Tresguerres JA (2005). Growth hormone prevents neuronal loss in the aged rat 
hippocampus. Neurobiol Aging. 26:697-703. 
Barclay DC, Hallbergson AF, Montague JR, Mudd LM (2005). Reversal of ethanol toxicity in 
embryonic neurons with growth factors and estrogen. Brain Res Bull. 67:459- 465. 
Bazov I, Kononenko O, Watanabe H, Kuntić V, Sarkisyan D, Taqi MM, Hussain MZ, Nyberg 
F, Yakovleva T, Bakalkin G (2011). The endogenous opioid system in human 
alcoholics: molecular adaptations in brain areas involved in cognitive control of 
addiction. Addict Biol. 2011 Sep 28. doi: 10.1111/j. 
Beatty WW, Katzung VM, Moreland VJ, Nixon SJ (1995). Neuropsychological performance 
of recently abstinent alcoholics and cocaine abusers. Drug Alcohol Depend. 37:247-
253. 
Benfenati F (2007). Synaptic plasticity and the neurobiology of learning and memory. Acta 
Biomed. 78 Suppl 1:58-66. 
Bengtsson BA, Edén S, Lönn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tölli J, Sjöström 
L, Isaksson OG (1993). Treatment of adults with growth hormone (GH) deficiency 
with recombinant human GH. J Clin Endocrinol Metab. 76:309-317. 
www.intechopen.com
 
Cognitive Impairments in Drug Addicts 237 
Blagrove M, Seddon J, George S, Parrott AC, Stickgold R, Walker MP, Jones KA, Morgan MJ 
(2011). Procedural and declarative memory task performance, and the memory 
consolidation function of sleep, in recent and abstinent ecstasy/MDMA users. J 
Psychopharmacol. 25:465-477 
Bolla KI, Rothman R, Cadet JL (1999). Dose-related neurobehavioral effects of chronic 
cocaine use. J Neuropsychiatry Clin Neurosci. 11:361–369. 
Boronat MA, García-Fuster MJ, García-Sevilla JA (2001). Chronic morphine induces up- 
regulation up-regulation of the pro-apoptotic Fas receptor and down-regulation of 
the anti-apoptotic Bcl-2 oncoprotein in rat brain. Br J Pharmacol. 134:1263-1270. 
Burman P, Deijen JB (1998). Quality of life and cognitive function in patients with pituitary 
insufficiency. Psychother Psychosom. 67:154-167. 
Büttner A, Mall G, Penning R, Weis S (2000). The neuropathology of heroin abuse. Forensic 
Sci Int. 2000 Sep 11;113(1-3):435-42. 
Cairney S, Clough A, Jaragba M, Maruff P (2007). Cognitive impairment in Aboriginal 
people with heavy episodic patterns of alcohol use. Addiction.102:909-915. 
Canales JJ (2010). Comparative neuroscience of stimulant-induced memory dysfunction: role 
for neurogenesis in the adult hippocampus. Behav Pharmacol. 21:379-393. 
Carhart-Harris RL, King LA, Nutt DJ (2011). A web-based survey on mephedrone. Drug 
Alcohol Depend. 118:19-22. 
Carvalho F (2009). How bad is accelerated senescence in consumers of drugs of abuse? 
Adicciones. 21:99-104. English, Spanish. 
Chummun H, Tilley V, Ibe J (2010). 3,4-methylenedioxyamfetamine (ecstasy) use reduces 
cognition. Br J Nurs. 19:94-100. 
Ciccarone D (2011). Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, 
attempts at pharmacotherapy. Prim Care. 38:41-58. 
Cippitelli A, Damadzic R, Frankola K, Goldstein A, Thorsell A, Singley E, Eskay RL, Heilig 
M (2010). Alcohol-induced neurodegeneration, suppression of transforming 
growth factor-beta, and cognitive impairment in rats: prevention by group II 
metabotropic glutamate receptor activation. Biol Psychiatry. 67:823-830. 
Climent E, Pascual M, Renau-Piqueras J, Guerri C (2002). Ethanol exposure enhances cell 
death in the developing cerebral cortex: role of brain-derived neurotrophic factor 
and its signaling pathways. J Neurosci Res. 68:213-225. 
Cooke SF, Bliss TV (2005). Long-term potentiation and cognitive drug discovery. Curr Opin 
Investig Drugs. 6:25-34. 
Crews FT, Nixon K (2009). Mechanisms of neurodegeneration and regeneration in 
alcoholism. Alcohol Alcohol. 44(2):115-127. 
Donahue CP, Kosik KS, Shors TJ (2006). Growth hormone is produced within the 
hippocampus where it responds to age, sex, and stress. Proc Natl Acad Sci U S A. 
103:6031-6036. 
Duman RS, Malberg J, Nakagawa S (2001). Regulation of adult neurogenesis by 
psychotropic drugs and stress. J Pharmacol Exp Ther. 299:401-407. 
Dunn MJ, Killcross S (2007). Medial prefrontal cortex infusion of alpha-flupenthixol 
attenuates systemic d-amphetamine-induced disruption of conditional 
discrimination performance in rats.Psychopharmacology (Berl).192:347-355. 
www.intechopen.com
 
Brain Damage – Bridging Between Basic Research and Clinics 238 
Edelson M, Sharot T, Dolan RJ, Dudai Y (2011). Following the crowd: brain substrates of 
long-term memory conformity. Science. 333:108-11. 
Ehninger D, Kempermann G (2008). Neurogenesis in the adult hippocampus. Cell Tissue 
Res. 331:243-250. 
Eisch AJ, Harburg GC (2006). Opiates, psychostimulants, and adult hippocampal 
neurogenesis: Insights for addiction and stem cell biology. Hippocampus. 16:271- 
286. 
Eisch AJ, Barrot M, Schad CA, Self DW, Nestler EJ (2000). Opiates inhibit neurogenesis in 
the adult rat hippocampus. Proc Natl Acad Sci U S A. 97:7579-7584. 
Ersche KD, Clark L, London M, Robbins TW, Sahakian BJ (2006). Profile of executive and 
memory function associated with amphetamine and opiate dependence. 
Neuropsychopharmacology. 31:1036-1047. 
Fernández-Serrano MJ, Lozano O, Pérez-García M, Verdejo-García A (2010). Impact of 
severity of drug use on discrete emotions recognition in polysubstance abusers. 
Drug Alcohol Depend. 109:57-64. 
Fletcher PJ, Tenn CC, Sinyard J, Rizos Z, Kapur S (2007). A sensitizing regimen of 
amphetamine impairs visual attention in the 5-choice serial reaction time test: 
reversal by a D1 receptor agonist injected into the medial prefrontal cortex. 
Neuropsychopharmacology. 32:1122-1132. 
Fox HC, Jackson ED, Sinha R (2009). Elevated cortisol and learning and memory deficits in 
cocaine dependent individuals: relationship to relapse outcomes. 
Psychoneuroendocrinology. 34:1198-1207. 
Gass JT, Olive MF (2009). Positive allosteric modulation of mGluR5 receptors facilitates 
extinction of a cocaine contextual memory. Biol Psychiatry. 65:717-720. 
George O, Mandyam CD, Wee S, Koob GF (2008). Extended access to cocaine self- 
administration produces long-lasting prefrontal cortex-dependent working 
memory impairments. Neuropsychopharmacology. 33:2474-2482. 
Gibson EM, Henson ES, Haney N, Villanueva J, Gibson SB (2002). Epidermal growth factor 
protects epithelial-derived cells from tumor necrosis factor-related apoptosis-
inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Res. 
62:488-496. 
Glannon W (2006). Psychopharmacology and memory. J Med Ethics. 32:74-78. Review. 
Glass JM, Buu A, Adams KM, Nigg JT, Puttler LI, Jester JM, Zucker RA (2009). Effects of 
alcoholism severity and smoking on executive neurocognitive function. Addiction. 
104:38-48. 
Goldstein, R.Z., Volkow, N.D. (2002). Drug addiction and its underlying neurobiologi- cal 
basis: neuroimaging evidence for the involvement of the frontal cortex. Am J 
Psychiatry. 159:1642-1652.  
Gould TJ (2010). Addiction and cognition. Addict Sci Clin Pract. 5:4-14. 
Gouzoulis-Mayfrank E, Daumann J (2009). Neurotoxicity of drugs of abuse--the case of 
methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines. Dialogues 
Clin Neurosci.11:305-317. 
Gonzales R, Mooney L, Rawson RA (2010). The methamphetamine problem in the United 
States. Annu Rev Public Health. 31:385-398. 
www.intechopen.com
 
Cognitive Impairments in Drug Addicts 239 
Gravius A, Pietraszek M, Schmidt WJ, Danysz W (2006). Functional interaction of NMDA 
and group I metabotropic glutamate receptors in negatively reinforced learning in 
rats. Psychopharmacology (Berl). 185:58-65. 
Gruber SA, Silveri MM, Yurgelun-Todd DA (2007). Neuropsychological consequences of 
opiate use. Neuropsychol Rev. 17:299-315. 
Guerra D, Solé A, Camí J, Tobeña A (1987). Neuropsychological performance in opiate 
addicts after rapid detoxification. Drug Alcohol Depend. 20:261-270. 
Guerri C, Pascual M (2010). Mechanisms involved in the neurotoxic, cognitive, and 
neurobehavioral effects of alcohol consumption during adolescence. Alcohol. 44:15-
26. 
Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, 
Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, 
Hanson GR, Fleckenstein AE (2011). 4-Methylmethcathinone (mephedrone): 
neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp 
Ther. 339:530-536. 
Harburg GC, Hall FS, Harrist AV, Sora I, Uhl GR, Eisch AJ (2007). Knockout of the mu 
opioid receptor enhances the survival of adult-generated hippocampal granule cell 
neurons. Neuroscience. 144:77-87 
Harvey S, Baudet ML, Sanders EJ (2006). Growth hormone and cell survival in the neural 
retina: caspase dependence and independence. Neuroreport. 17:1715-1718.  
Hauser KF, Houdi AA, Turbek CS, Elde RP, Maxson W 3rd (2000). Opioids intrinsically 
inhibit the genesis of mouse cerebellar granule neuron precursors in vitro: 
differential impact of mu and delta receptor activation on proliferation and neurite 
elongation. Eur J Neurosci. 12:1281-1293. 
He L, Li H, Chen L, Miao J, Jiang Y, Zhang Y, Xiao Z, Hanley G, Li Y, Zhang X, LeSage G, 
Peng Y, Yin D (2011). Toll-like receptor 9 is required for opioid-induced microglia 
apoptosis. PLoS One. 2011 Apr 29;6(4):e18190. 
Hoffman R, Al'Absi M (2010). Khat use and neurobehavioral functions: suggestions for 
future studies. J Ethnopharmacol. 132:554-563 
Hu S, Sheng WS, Lokensgard JR, Peterson PK (2002). Morphine induces apoptosis of human 
microglia and neurons. Neuropharmacology. 42:829-836. 
Hyman SE (2005). Addiction: a disease of learning and memory. Am J Psychiatry. 162:1414-
1422.  
Isgaard J, Aberg D, Nilsson M (2007). Protective and regenerative effects of the GH/IGF-I 
axis on the brain. Minerva Endocrinol. 32:103-113. 
Kaushal N, Matsumoto RR (2011). Role of sigma receptors in methamphetamine-induced 
neurotoxicity. Curr Neuropharmacol. 9:54-57. 
Kalivas PW (2004). Glutamate systems in cocaine addiction. Curr Opin Pharmacol. 4:23- 29. 
Review. 
Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, Yoshitake T (2011). 
Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly 
increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J 
Pharmacol. 164:1949-1958. 
www.intechopen.com
 
Brain Damage – Bridging Between Basic Research and Clinics 240 
Kenney JW, Gould TJ (2008). Modulation of hippocampus-dependent learning and synaptic 
plasticity by nicotine. Mol Neurobiol. 38:101-121 
Kim J, Lee I (2011). Hippocampus is necessary for spatial discrimination using distal cue- 
configuration. Hippocampus. 21:609-621.  
Kopelman MD, Thomson AD, Guerrini I, Marshall EJ (2009). The Korsakoff syndrome: 
clinical aspects, psychology and treatment. Alcohol Alcohol. 44:148-154 
Krasnova IN, Ladenheim B, Cadet JL (2005). Amphetamine induces apoptosis of medium 
spiny striatal projection neurons via the mitochondria-dependent pathway. FASEB 
J. 19:851-853 Psychiatry 159, 1642–1652. 
Kubota M, Nakazaki S, Hirai S, Saeki N, Yamaura A, Kusaka T (2001). Alcohol consumption 
and frontal lobe shrinkage: study of 1432 non-alcoholic subjects. J Neurol 
Neurosurg Psychiatry. 71:104-106. 
Kuribayashi K, Mayes PA, El-Deiry WS (2006). What are caspases 3 and 7 doing upstream of 
the mitochondria? Cancer Biol Ther. 5:763-765. 
Lai Z, Roos P, Zhai O, Olsson Y, Fholenhag K, Larsson C, Nyberg F (1993). Age-related 
reduction of human growth hormone-binding sites in the human brain. Brain Res. 
621:260-266. 
Le Greves M, Steensland P, Le Greves P, Nyberg F (2002). Growth hormone induces age- 
dependent alteration in the expression of hippocampal growth hormone receptor 
and N-methyl-D-aspartate receptor subunits gene transcripts in male rats. Proc 
Natl Acad Sci U S A. 99:7119-7123. 
Le Greves M, Zhou Q, Berg M, Le Greves P, Fholenhag K, Meyerson B, Nyberg F (2006). 
Growth hormone replacement in hypophysectomized rats affects spatial 
performance and hippocampal levels of NMDA receptor subunit and PSD-95 gene 
transcript levels. Exp Brain Res. 173:267-273. 
Le Grevès M, Enhamre E, Zhou Q, Fhölenhag K, Berg M, Meyerson B, Nyberg F (2011). 
Growth Hormone Enhances Cognitive Functions in Hypophys-Ectomized Male 
Rats Am. J. Neuroprotec. Neuroregen. 3:53-58. 
Lichtenwalner RJ, Forbes ME, Bennett SA, Lynch CD, Sonntag WE, Riddle DR (2001). 
Intracerebroventricular infusion of insulin-like growth factor-I ameliorates the age- 
related decline in hippocampal neurogenesis. Neuroscience. 107:603-613 
Loeber S, Duka T, Welzel H, Nakovics H, Heinz A, Flor H, Mann K (2009). Impairment of 
cognitive abilities and decision making after chronic use of alcohol: the impact of 
multiple detoxifications. Alcohol Alcohol. 44:372-381. 
Lu G, Zhou QX, Kang S, Li QL, Zhao LC, Chen JD, Sun JF, Cao J, Wang YJ, Chen J, Chen XY, 
Zhong DF, Chi ZQ, Xu L, Liu JG (2010). Chronic morphine treatment impaired 
hippocampal long-term potentiation and spatial memory via accumulation of 
extracellular adenosine acting on adenosine A1 receptors. J Neurosci. 30:5058- 5070. 
Mao J, Sung B, Ji RR, Lim G (2002). Neuronal apoptosis associated with morphine tolerance: 
Evidence for an opioid-induced neurotoxic mechanism. J Neurosci. 22:7650–7661.  
McKetin, R., and Mattick, R. P. (1997) Attention and memory in illicit amphetamine users. 
Drug Alcohol Depend. 48:235–242. 
www.intechopen.com
 
Cognitive Impairments in Drug Addicts 241 
McMillan CV, Bradley C, Gibney J, Healy ML, Russell-Jones DL, Sönksen PH (2003). 
Psychological effects of withdrawal of growth hormone therapy from adults with 
growth hormone deficiency. Clin Endocrinol (Oxf). 59:467-475. 
Mintzer MZ, Stitzer ML (2002). Cognitive impairment in methadone maintenance patients. 
Drug Alcohol Depend. 67:41-51. 
Muriach M, López-Pedrajas R, Barcia JM, Sanchez-Villarejo MV, Almansa I, Romero FJ 
(2010). Cocaine causes memory and learning impairments in rats: involvement of 
nuclear factor kappa B and oxidative stress, and prevention by topiramate. J 
Neurochem. 114:675-684. 
Moghaddam B (2004). Targeting metabotropic glutamate receptors for treatment of the 
cognitive symptoms of schizophrenia. Psychopharmacology (Berl). 174:39-44. 
Nash RJ, Heimburg-Molinaro J, Nash RJ (2009). Heparin binding epidermal growth factor- 
like growth factor reduces ethanol-induced apoptosis and differentiation in human 
embryonic stem cells. Growth Factors. 27:362-369. 
Nestor LJ, Ghahremani DG, Monterosso J, London ED (2011). Prefrontal hypoactivation 
during cognitive control in early abstinent methamphetamine-dependent subjects. 
Psychiatry Res. 194(:287-295 
Nixon K, Crews FT (2002). Binge ethanol exposure decreases neurogenesis in adult rat 
hippocampus. J Neurochem. 83:1087-1093. 
Nixon K, McClain JA (2010). Adolescence as a critical window for developing an alcohol use 
disorder: current findings in neuroscience. Curr Opin Psychiatry. 23:227-232.  
Nulsen CE, Fox AM, Hammond GR (2010). Differential effects of ecstasy on short-term and 
working memory: a meta-analysis. Neuropsychol Rev. 20:21-32. 
Nyberg F (2000). Growth hormone in the brain: characteristics of specific brain targets for 
the hormone and their functional significance. Front Neuroendocrinol. 21:330-348.  
Nyberg F (2007). Growth hormone and brain function. In Ranke MB, Price DA, Reiter EO 
(eds.) Growth Hormone Therapy in Pediatrics. 20 years of KIGS. Karger, Basel, pp 
450-460. 
Nyberg F (2009). The role of the somatotrophic axis in neuroprotection and 
neuroregeneration of the addictive brain. Int Rev Neurobiol. 88:399-427. 
O'Kusky JR, Ye P, D'Ercole AJ (2000). Insulin-like growth factor-I promotes neurogenesis 
and synaptogenesis in the hippocampal dentate gyrus during postnatal 
development. J Neurosci. 20:8435-8442. 
Olive MF (2009). Metabotropic glutamate receptor ligands as potential therapeutics for 
addiction. Curr Drug Abuse Rev. 2:83-98. 
Olive MF (2010). Cognitive effects of Group I metabotropic glutamate receptor ligands in the 
context of drug addiction. Eur J Pharmacol. 639:47-58. 
Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ, Robbins TW 
(2000). Profiles of cognitive dysfunction in chronic amphetamine and heroin 
abusers. Neuropsychopharmacology. 23:113-126 
Parrott AC, Lasky J (1998). Ecstasy (MDMA) effects upon mood and cognition: before, 
during and after a Saturday night dance. Psychopharmacology (Berl). 139:261-268. 
www.intechopen.com
 
Brain Damage – Bridging Between Basic Research and Clinics 242 
Reichel CM, Ramsey LA, Schwendt M, McGinty JF, See RE (2011). Methamphetamine- 
induced changes in the object recognition memory circuit. Neuropharmacology. 
2011 Nov 18. [Epub ahead of print]. 
Reske M, Eidt CA, Delis DC, Paulus MP (2010). Nondependent stimulant users of cocaine 
and prescription amphetamines show verbal learning and memory deficits. Biol 
Psychiatry. 68:762-769. 
Ridderinkhof KR, van den Wildenberg WP, Segalowitz SJ, Carter CS (2004). Neurocognitive 
mechanisms of cognitive control: the role of prefrontal cortex in action selection, 
response inhibition, performance monitoring, and reward-based learning. Brain 
Cogn. 56:129-140.  
Rogers G, Elston J, Garside R, et al. (2009) The harmful health effects of recreational ecstasy: 
A systematic review of observational evidence. Health Technol Assess 13: 1–315. 
Samuelson KW (2011). Post-traumatic stress disorder and declarative memory functioning: a 
review. Dialogues Clin Neurosci. 13:346-351. 
Santini E, Muller RU, Quirk GJ (2001). Consolidation of extinction learning involves transfer 
from NMDA-independent to NMDA-dependent memory. J Neurosci. 21:9009-9017. 
Seiler AE, Ross BN, Green JS, Rubin R (2000). Differential effects of ethanol on insulin- like 
growth factor-I receptor signaling. Alcohol Clin Exp Res. 24:140-148. 
Silva AP, Martins T, Baptista S, Gonçalves J, Agasse F, Malva JO (2010). Brain injury 
associated with widely abused amphetamines: neuroinflammation, neurogenesis 
and blood-brain barrier. Curr Drug Abuse Rev. 3:239-254 
Simonyi A, Schachtman TR, Christoffersen GR (2005).The role of metabotropic glutamate 
receptor 5 in learning and memory processes. Drug News Perspect. 18:353-361. 
Soyka M, Limmer C, Lehnert R, Koller G, Martin G, Küfner H, Kagerer S, Haberthür A 
(2011). A comparison of cognitive function in patients under maintenance 
treatment with heroin, methadone, or buprenorphine and healthy controls: an open 
pilot study. Am J Drug Alcohol Abuse. 37:497-508. 
Spain JW, Newsom GC (1991). Chronic opioids impair acquisition of both radial maze and 
Y-maze choice escape. Psychopharmacology (Berl). 105:101-106 
Stramiello M, Wagner JJ (2010). Cocaine enhancement of long-term potentiation in the CA1 
region of rat hippocampus: lamina-specific mechanisms of action. Synapse. 64:644-
648. 
Sudai E, Croitoru O, Shaldubina A, Abraham L, Gispan I, Flaumenhaft Y, Roth-Deri I, Kinor 
N, Aharoni S, Ben-Tzion M, Yadid G (2011). High cocaine dosage decreases 
neurogenesis in the hippocampus and impairs working memory. Addict Biol. 
16:251-260. 
Sullivan EV, Pfefferbaum A (2005). Neurocircuitry in alcoholism: a substrate of disruption 
and repair. Psychopharmacology (Berl). 180:583-594. 
Sun LY, Al-Regaiey K, Masternak MM, Wang J, Bartke A (2005). Local expression of GH and 
IGF-1 in the hippocampus of GH-deficient long-lived mice. Neurobiol Aging. 
26:929-937. 
Svensson AL, Bucht N, Hallberg M, Nyberg F (2008). Reversal of opiate-induced apoptosis 
by human recombinant growth hormone in murine foetus primary hippocampal 
neuronal cell cultures. Proc Natl Acad Sci U S A. 105:7304-7308. 
www.intechopen.com
 
Cognitive Impairments in Drug Addicts 243 
Taffe MA, Kotzebue RW, Crean RD, Crawford EF, Edwards S, Mandyam CD (2010). Long-
lasting reduction in hippocampal neurogenesis by alcohol consumption in 
adolescent nonhuman primates. Proc Natl Acad Sci U S A.107:11104-11109. 
Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ (1999). 
Genetic enhancement of learning and memory in mice. Nature. 401:63-69.  
Taqi MM, Bazov I, Watanabe H, Sheedy D, Harper C, Alkass K, Druid H, Wentzel P, Nyberg 
F, Yakovleva T, Bakalkin G (2011). Prodynorphin CpG-SNPs associated with 
alcohol dependence: elevated methylation in the brain of human alcoholics. Addict 
Biol. 16:499-509. 
Tateno M, Ukai W, Ozawa H, Yamamoto M, Toki S, Ikeda H, Saito T (2004). Ethanol 
inhibition of neural stem cell differentiation is reduced by neurotrophic factors. 
Alcohol Clin Exp Res. 2004 Aug;28(8 Suppl Proceedings):134S-138S. 
Tedstone D, Coyle K (2004). Cognitive impairments in sober alcoholics: performance on 
selective and divided attention tasks. Drug Alcohol Depend. 75:277-286. 
Thompson AM, Swant J, Wagner JJ (2005). Cocaine-induced modulation of long-term 
potentiation in the CA1 region of rat hippocampus. Neuropharmacology. 49:185– 
194. 
Thornwall-Le Greves M, Zhou Q, Lagerholm S, Huang W, Le Greves P, Nyberg F (2001). 
Morphine decreases the levels of the gene transcripts of growth hormone receptor 
and growth hormone binding protein in the male rat hippocampus and spinal cord. 
Neurosci Lett. 304:69-72 
Tramullas M, Martínez-Cué C, Hurlé MA (2007). Chronic methadone treatment and 
repeated withdrawal impair cognition and increase the expression of apoptosis- 
related proteins in mouse brain. Psychopharmacology (Berl). 193:107-120. 
Tzschentke TM, Schmidt WJ (2003). Glutamatergic mechanisms in addiction. Mol 
Psychiatry. 8:373-382. 
van Dam PS, Aleman A, de Vries WR, Deijen JB, van der Veen EA, de Haan EH, 
Koppeschaar HP (2000). Growth hormone, insulin-like growth factor I and 
cognitive function in adults. Growth Horm IGF Res. 10 Suppl B:S69-73.  
Vardakou I, Pistos C, Spiliopoulou Ch (2011). Drugs for youth via Internet and the example 
of mephedrone. Toxicol Lett. 201:191-195. 
Venkatesan A, Uzasci L, Chen Z, Rajbhandari L, Anderson C, Lee MH, Bianchet MA, Cotter 
R, Song H, Nath A (2011). Impairment of adult hippocampal neural progenitor 
proliferation by methamphetamine: role for nitrotyrosination. Mol Brain. 2011 Jun 
27;4:28. 
Weiss C, Disterhoft JF (2011). Exploring prefrontal cortical memory mechanisms with 
eyeblink conditioning. Behav Neurosci. 125:318-326. 
Wolf ME (1998). The role of excitatory amino acids in behavioral sensitization to 
psychomotor stimulants. Prog Neurobiol. 54:679-720. Review 
Xu TX, Ma Q, Spealman RD, Yao WD (2010). Amphetamine modulation of long-term 
potentiation in the prefrontal cortex: dose dependency, monoaminergic 
contributions, and paradoxical rescue in hyperdopaminergic mutant. J Neurochem. 
115:1643-1654. 
www.intechopen.com
 
Brain Damage – Bridging Between Basic Research and Clinics 244 
Yang Z, Xie J, Shao YC, Xie CM, Fu LP, Li DJ, Fan M, Ma L, Li SJ (2009). Dynamic neural 
responses to cue-reactivity paradigms in heroin-dependent users: an fMRI study. 
Hum Brain Mapp. 30:766-775. 
Zhai QZ, Lai Z, Yukhananov R, Roos P, Nyberg F (1995). Decreased binding of growth 
hormone in the rat hypothalamus and choroid plexus following morphine 
treatment. Neurosci Lett. 23;184:82-85 
Zhao MG, Toyoda H, Lee YS, Wu LJ, Ko SW, Zhang XH, Jia Y, Shum F, Xu H, Li BM, Kaang 
BK, Zhuo M. Roles of NMDA NR2B subtype receptor in prefrontal long- term 
potentiation and contextual fear memory. Neuron. 2005; 47:859-872. 
www.intechopen.com
Brain Damage - Bridging Between Basic Research and Clinics
Edited by Dr. Alina Gonzalez-Quevedo
ISBN 978-953-51-0375-2
Hard cover, 282 pages
Publisher InTech
Published online 16, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
"Brain Damage - Bridging Between Basic Research and Clinics" represents a collection of papers in an attempt
to provide an up-to-date approach to the fascinating topic of brain damage in different pathological situations,
combining the authors' personal experiences with current knowledge in this field. In general, the necessary link
between basic and clinical neurosciences is highlighted, as it is through this interaction that the theoretical
understanding of the pathophysiological mechanisms can be successfully translated into better ways to
diagnose, treat and prevent the catastrophic events that occur when the brain suffers from external or internal
noxious events. The book spans different aspects of brain injury, starting from damage occurring in the fetal
and child brain, followed by different neurodegenerative processes. Attention is also focused on the negative
effects of drug addictions and sleep deprivation on the brain, as well as on the early assessment of brain injury
for preventive strategies employing sensitive biomarkers.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Fred Nyberg (2012). Cognitive Impairments in Drug Addicts, Brain Damage - Bridging Between Basic
Research and Clinics, Dr. Alina Gonzalez-Quevedo (Ed.), ISBN: 978-953-51-0375-2, InTech, Available from:
http://www.intechopen.com/books/brain-damage-bridging-between-basic-research-and-clinics/cognitive-
impairments-in-drug-addicts
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
